Selleck Chemicals supplies over 3,000 inhibitors used in the study of cell signaling pathways. We actively tracks the latest science so our customers can rely on us to be the leading supplier of the newest inhibitors.
Company WebsiteEmodin-8-glucoside (Emodin glucoside B, Anthraglycoside B, Emodin glucoside B) is an anthraquinone derivative isolated from Aloe vera, binds to minor groove of DNA.
More Information Supplier PageEMPA is a selective OX2 receptor antagonist and binds to human and rat OX2-HEK293 membranes with Kd values of 1.1 and 1.4 nM respectively.
More Information Supplier PageEMPA is a selective OX2 receptor antagonist and binds to human and rat OX2-HEK293 membranes with Kd values of 1.1 and 1.4 nM respectively.
More Information Supplier PageEmpagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.
More Information Supplier PageEmpagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.
More Information Supplier PageEmpagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.
More Information Supplier PageEmpagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.
More Information Supplier PageEmpagliflozin is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.
More Information Supplier PageEmpesertib (BAY1161909, Mps1-IN-5), a derivative of triazolopyridine, is an orally bioavailable, selective inhibitor of the serine/threonine monopolar spindle 1 (Mps1) kinase with IC50 of
More Information Supplier PageEmricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
More Information Supplier PageEmricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
More Information Supplier PageEmricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
More Information Supplier PageEmricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
More Information Supplier PageEmricasan (IDN-6556, PF 03491390, PF-03491390) is a potent irreversible pan-caspase inhibitor. Emricasan is an inhibitor of Zika virus infection.
More Information Supplier PageEmtricitabine (FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.
More Information Supplier PageEmtricitabine (FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.
More Information Supplier PageEmtricitabine (FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.
More Information Supplier PageEmtricitabine (FTC) is a new nucleoside agent that has activity against both human immunodeficiency virus (HIV) and hepatitis B virus. It is a reverse transcriptase inhibitor. Intracellular half-life is 39 h.
More Information Supplier PageEmvododstat(PTC299), a post-transcriptional inhibitor of pathogenic VEGF and dihydroorotate dehydrogenase(DHODH), inhibits VEGFA mRNA translation and abnormal cell proliferation. In HeLa cells PTC299 inhibits hypoxia-induced VEGFA protein production with an EC50 of 1.64 nM.
More Information Supplier PageEN4, a covalent ligand that targets cysteine 171 (C171) of MYC, is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.
More Information Supplier PageEN4, a covalent ligand that targets cysteine 171 (C171) of MYC, is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.
More Information Supplier PageEN4, a covalent ligand that targets cysteine 171 (C171) of MYC, is selective for c-MYC over N-MYC and L-MYC. EN4 inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.
More Information Supplier PageEN450 is a cysteine-reactive covalent molecular glue degrader targeting NF-κB. It interacts with allosteric C111 in the E2 ubiquitin ligase UBE2D that induces the ternary complex formation between UBE2D and NFKB1. It exhibits anti-proliferative effects through a Cullin E3 ligase and proteasome-dependent mechanism.
More Information Supplier PageEN450 is a cysteine-reactive covalent molecular glue degrader targeting NF-κB. It interacts with allosteric C111 in the E2 ubiquitin ligase UBE2D that induces the ternary complex formation between UBE2D and NFKB1. It exhibits anti-proliferative effects through a Cullin E3 ligase and proteasome-dependent mechanism.
More Information Supplier PageEN460 is a small-molecule inhibitor of endoplasmic reticulum oxidation 1(ERO1), which is specific for the reduced active form of ERO1α and prevents re-oxidation. It also protects cells from erastin-induced ferroptosis.
More Information Supplier PageEN460 is a small-molecule inhibitor of endoplasmic reticulum oxidation 1(ERO1), which is specific for the reduced active form of ERO1α and prevents re-oxidation. It also protects cells from erastin-induced ferroptosis.
More Information Supplier PageEN460 is a small-molecule inhibitor of endoplasmic reticulum oxidation 1(ERO1), which is specific for the reduced active form of ERO1α and prevents re-oxidation. It also protects cells from erastin-induced ferroptosis.
More Information Supplier PageEN460 is a small-molecule inhibitor of endoplasmic reticulum oxidation 1(ERO1), which is specific for the reduced active form of ERO1α and prevents re-oxidation. It also protects cells from erastin-induced ferroptosis.
More Information Supplier PageEN6 is a novel covalent autophagy activator and targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase with an IC50 of 1.7 μM for recombinant human ATP6V1A protein.
More Information Supplier PageEN6 is a novel covalent autophagy activator and targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase with an IC50 of 1.7 μM for recombinant human ATP6V1A protein.
More Information Supplier PageEN6 is a novel covalent autophagy activator and targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase with an IC50 of 1.7 μM for recombinant human ATP6V1A protein.
More Information Supplier PageEN6 is a novel covalent autophagy activator and targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase with an IC50 of 1.7 μM for recombinant human ATP6V1A protein.
More Information Supplier PageEN6 is a novel covalent autophagy activator and targets cysteine 277 in the ATP6V1A subunit of the lysosomal v-ATPase with an IC50 of 1.7 μM for recombinant human ATP6V1A protein.
More Information Supplier PageEnalapril (MK-421) Maleate is an angiotensin-converting enzyme (ACE) inhibitor, used in the treatment of hypertension, diabetic nephropathy, and chronic heart failure.
More Information Supplier PageEnalapril (MK-421) Maleate is an angiotensin-converting enzyme (ACE) inhibitor, used in the treatment of hypertension, diabetic nephropathy, and chronic heart failure.
More Information Supplier PageEnalaprilat (MK-422) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.
More Information Supplier PageEnalaprilat (MK-422) is an angiotensin-converting enzyme (ACE) inhibitor with IC50 of 1.94 nM.
More Information Supplier PageEnapotamab(Anti-AXL / UFO) is a highly specific rabbit polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It demonstrates potent activity in immunotherapeutic strategy for the treatment of sarcomas. MW :145.42 KD.
More Information Supplier PageEnapotamab(Anti-AXL / UFO) is a highly specific rabbit polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It demonstrates potent activity in immunotherapeutic strategy for the treatment of sarcomas. MW :145.42 KD.
More Information Supplier PageEnapotamab(Anti-AXL / UFO) is a highly specific rabbit polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It demonstrates potent activity in immunotherapeutic strategy for the treatment of sarcomas. MW :145.42 KD.
More Information Supplier PageEnapotamab vedotin (EnaV, HuMAX-AXL-ADC) is an AXL-specific human IgG1 antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) through a protease cleavable valine-citrulline (vc) linker.
More Information Supplier PageEnapotamab vedotin (EnaV, HuMAX-AXL-ADC) is an AXL-specific human IgG1 antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) through a protease cleavable valine-citrulline (vc) linker.
More Information Supplier PageEnarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.
More Information Supplier PageEnarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.
More Information Supplier PageEnarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.
More Information Supplier PageEnarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.
More Information Supplier PageEnarodustat (JTZ-951) is a potent and orally active HIF prolyl hydroxylase inhibitor with IC50 of 0.22 μM for PHD2 and EC50 of 5.7 μM for EPO release from Hep3B cells. Enarodustat has the potential for the treatment of renal anemia.
More Information Supplier PageEnasidenib (AG-221) is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzyme.
More Information Supplier PageEnasidenib (AG-221) is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzyme.
More Information Supplier PageEnasidenib (AG-221) is a first-in-class, oral, potent, reversible, selective inhibitor of the IDH2 mutant enzyme.
More Information Supplier Page
